80 completed, 37 unknown, 20 terminated, 18 recruiting. 49 Phase 2, 42 Phase 3, 40 Not applicable, 39 Phase 4, 17 Phase 1.
Follow Rifaximin: new trials by email Literature Review of Rifaximin trials Research Report on Rifaximin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SIMBA in Irritable Bowel Syndrome (IBS) Rifaximin (drug), fluid biopsy capsule - Irritable Bowel Syndrome (IBS), Microbiome | Phase 1 | Not yet recruiting | University of Calgary | 180 | 2026-11-01 | 2026-10-20 |
| Comparison of the Efficacy of Saccharomyces Boulardii and Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth Saccharomyces boulardii sachets, Rifaximin (Xifaxan) - Small Intestinal Bacterial Overgrowth Syndrome (SIBO) | Phase 4 | Not yet recruiting | Shandong University | 222 | 2026-09-10 | 2026-09-15 |
| Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery Rifaximin (Xifaxan), Metronidazole, Neomycin Sulfate - Surgical Site Infection, Colon Surgery | Phase 4 | Not yet recruiting | Universität Luzern | 458 | 2026-06-01 | 2025-09-18 |
| Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders Rifaximin (drug), Placebo - Bloating, Rifaximin | Phase 3 | Not yet recruiting | Mahidol University | 78 | 2026-04-01 | 2026-04-13 |
| Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial Probiotic preparation, Placebo, Rifaximin (drug) - Small Intestinal Bacterial Overgrowth Syndrome (SIBO), IBS | Phase 4 | Not yet recruiting | Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji | 100 | 2026-02-15 | 2026-02-23 |
| Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT) - Diarrhea, Gastroenteritis | Phase 4 | Recruiting | Bausch Health Americas, Inc. | 54 | 2026-02-11 | 2026-08-13 |
| Efficacy of Rifaximin With NAC in IBS-D rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo - IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 2 | Recruiting | Mark Pimentel, MD | 225 | 2026-02-04 | 2026-04-20 |
| Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance Rifaximin, Biospecimen Collection - IgA Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 50 | 2026-01-22 | 2026-08-17 |
| Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor Rifaximin - ACS - Acute Coronary Syndrome, Ticagrelor | Phase 4 | Not yet recruiting | Collegium Medicum w Bydgoszczy | 50 | 2026-01-01 | 2025-10-02 |
| Rifaximin for Treatment of Bloating in Children and Adults With Cystic Fibrosis Rifaximin 550 MG Oral Tablet [XIFAXAN], Placebo - Cystic Fibrosis, Abdominal Pain | Phase 2 / Phase 3 | Withdrawn | Wake Forest University Health Sciences | 2025-07-01 | 2025-06-27 | |
| Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE) Human albumin infusion at a modified dosage, Human albumin infusion at a routine dosage, Lactulose - Overt Hepatic Encephalopathy | Not applicable | Recruiting | General Hospital of Shenyang Military Region | 174 | 2025-06-24 | 2025-08-26 |
| Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating. Rifaximin (drug) - SIBO | Not applicable | Recruiting | Xiuli Zuo | 115 | 2025-04-15 | 2025-05-16 |
| Goal Directed Ammonia Lowering Therapy in Hyperammonemic ACLF Patients With no Overt HE to Reduce Major Adverse Liver Related Outcomes (GOAL Trial) Lactulose, Rifaximin, Standard Medical treatment - Acute on Chronic Liver Failure | Not applicable | Not yet recruiting | Institute of Liver and Biliary Sciences, India | 90 | 2025-02-05 | 2025-02-04 |
| BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose - Hepatic Encephalopathy, Decompensated Cirrhosis | Phase 4 | Recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 336 | 2025-02-01 | 2025-06-10 |
| Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients Rifaximin 550 MG, Standard Care Chemoradiation - Radiotherapy Induced Diarrhea, Acute Radiation Enteritis | Phase 1 / Phase 2 | Not yet recruiting | Mansoura University | 80 | 2025-01-20 | 2025-01-20 |
| A Trial for Comparing Rifaximin, Probiotic and L-ornithine- L Aspartate With Lactulose in Overt Hepatic Encephalopathy. Probiotic plus lactulose, Rifaximin plus lactulose, L-ornithine-L-aspartate plus latulose - Overt Hepatic Encephalopathy | Phase 4 | Completed | Qurratul Ain Jamil | 252 | 2024-12-02 | 2025-06-25 |
| Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant Rifaximin 550 MG, SOC - Chronic Liver Disease | Not applicable | Recruiting | Institute of Liver and Biliary Sciences, India | 100 | 2024-12-01 | 2025-03-05 |
| Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction Rifaximin, Standard HFpEF treatment - Bacterial Overgrowth Syndrome Small Bowel, Heart Failure with Preserved Ejection Fraction | Not applicable | Recruiting | I.M. Sechenov First Moscow State Medical University | 40 | 2024-09-02 | 2024-10-22 |
| Efficacy and Safety of Rifaximin in Treating MAFLD Rifaximin (Xifaxan) - Metabolic-associated Fatty Liver Disease | Early Phase 1 | Recruiting | Shanghai Changzheng Hospital | 40 | 2024-08-10 | 2025-09-22 |
| Effect of Rifaximin on Gut Bacterial Flora Post Stem Cell Transplant in Patients With Acute Leukemia Rifaximin 200Mg Tab, allogenic hematopoietic stem cell transplantation - Acute Leukemia | Phase 2 | Recruiting | Tata Memorial Centre | 166 | 2024-08-02 | 2025-07-31 |
Showing 20 of 176. Sign in to see all of them.
Hepatic Encephalopathy (26) · Liver Cirrhosis (21) · Diarrhea (18) · Irritable Bowel Syndrome (16) · Fibrosis (15) · Crohn Disease (6) · Inflammation (6) · Hepatitis C (5) · Parkinson Disease (5) · Acute-On-Chronic Liver Failure (4) · Ascites (4) · Hypertension, Portal (4) · Liver Diseases (4) · Abdominal Pain (3) · Hepatic Insufficiency (3)
Bausch Health Americas, Inc. (15) · Institute of Liver and Biliary Sciences, India (7) · Mayo Clinic (5) · Cedars-Sinai Medical Center (4) · Shanghai Changzheng Hospital (4) · Shanghai Zhongshan Hospital (4) · Emory University (3) · University of Michigan (3) · Ain Shams University (2) · Bezmialem Vakif University (2) · Changi General Hospital (2) · Columbia University (2) · Henry C. Lin, MD (2) · Henry M. Jackson Foundation for the Advancement of Military Medicine (2) · Hunter Holmes Mcguire Veteran Affairs Medical Center (2)
United States (63) · China (19) · India (11) · Egypt (10) · Italy (10) · Mexico (8) · United Kingdom (8) · France (5) · Germany (5) · Spain (5) · Belgium (4) · Canada (3) · Kenya (3) · Netherlands (3) · Singapore (3)
Lindsey Mathew (3) · Enoch Bortey (2) · Jason Stubbs, MD (2) · Mark Pimentel, MD (2) · Wei-Fen Xie, MD (2) · Ahmed A. Gomaa, MD (1) · Aida Jawhari, MD (1) · Ajay Nooka, MD (1) · Alexandra Heurgue-Berlot, MD (1) · Alexandre Louvet, MD, PhD (1) · Allan R. Tenorio, M.D. (1) · Allen Lee, MD (1) · Asem A Elfert (1)
PMID 37467180, PMID 24697851, PMID 36922331, PMID 20335583, PMID 20849805, PMID 21157444, PMID 21208106, PMID 24365449, PMID 28994123, PMID 33385299, PMID 10453941, PMID 10898704, PMID 11786970, PMID 1397884, PMID 15862938, PMID 15897530, PMID 16521351, PMID 17043337, PMID 19210289, PMID 19302262, PMID 20412178, PMID 20633946, PMID 20675008, PMID 20804522, PMID 21240023, PMID 21647654, PMID 21848797, PMID 22098272, PMID 23171089, PMID 23526308, PMID 23565181, PMID 23872605, PMID 23993913, PMID 24012319, PMID 24161699, PMID 24314790, PMID 24914504, PMID 25133198, PMID 25214516, PMID 25819304, PMID 25932262, PMID 26084406, PMID 26644276, PMID 27512927, PMID 27528177, PMID 27558181, PMID 27775818, PMID 27795384, PMID 27885712, PMID 28112426
2014 (1), 2016 (1), 2017 (1), 2018 (1), 2025 (1), K23DK124567 (1), P30CA138292 (1), R03DK140415 (1), R21DK078101 (1), U01AI068636 (1)